Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Accumulated Expenses (2016 - 2025)

Mimedx's Accumulated Expenses history spans 15 years, with the latest figure at $31.1 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 31.26% year-over-year to $31.1 million; the TTM value through Dec 2025 reached $31.1 million, up 31.26%, while the annual FY2025 figure was $31.1 million, 31.26% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $31.1 million at Mimedx, up from $12.8 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $31.1 million in Q4 2025 and bottomed at $9.3 million in Q2 2024.
  • The 5-year median for Accumulated Expenses is $19.5 million (2024), against an average of $19.3 million.
  • The largest annual shift saw Accumulated Expenses tumbled 68.01% in 2022 before it soared 85.61% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $23.6 million in 2021, then decreased by 11.61% to $20.9 million in 2022, then increased by 7.18% to $22.4 million in 2023, then grew by 5.88% to $23.7 million in 2024, then surged by 31.26% to $31.1 million in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Accumulated Expenses are $31.1 million (Q4 2025), $12.8 million (Q3 2025), and $15.1 million (Q2 2025).